Effective 9/23/10
FDA significantly restricts use of rosiglitazone (Avandia, Avandaryl, Avandameta)

Due to data suggesting higher cardiovascular risk, such as heart attack and stroke, individuals with Type 2 diabetes who are not currently taking rosiglitazone can only be prescribed the medication if they are unable to achieve glycemic control with an alternative medication. Rosiglitazone will only be available to individuals who are currently taking the medication if they appear to be benefiting from the drug and have been counseled on the risks.

For further information:

Resistance to oseltamivir

Resistance to oseltamivir by specific strains of influenza have been reported. Check the CDC for the most current information and guidance at